50 CHF CHF 50.00
AG-CR1-3683-M01010 mgCHF 50.00
AG-CR1-3683-M05050 mgCHF 140.00
|Synonyms||RTV; A-84538; ABT-538; Abbot 84538; NSC 693184|
|Purity Chemicals||≥98% (HPLC)|
|Appearance||White to off-white solid.|
|Solubility||Soluble in DMSO (10mg/ml), DMF (10mg/ml) or EtOH.|
|Other Product Data||
Optical Rotation [α]D20 (c=2, MeOH): +7.0° to +10.0°.
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
|Handling Advice||Keep cool and dry.|
|Use/Stability||Stable for at least 2 years after receipt when stored at -20°C.|
|Product Specification Sheet|
- HIV-1 and HIV-2 protease inhibitor.
- Glucose transporter 1 (GLUT1) and 4 (GLUT4) inhibitor. Inhibits transport of glucose across the plasma membranes of mammalian cells and consequently decreases glycolysis.
- Useful agent for immunometabolism research.
- Antitumor agent. Apoptosis inducer and cell proliferation inhibitor in GLUT1/GLUT4 overexpressed cancer cell lines.
- Tumor cells rely on elevated glucose consumption and metabolism for survival and proliferation. Glucose transporters mediating glucose entry are key proximal rate-limiting checkpoints. Among the fourteen SLC2A family members, GLUTs 1 and 4 are high-affinity glucose transporters.
- Inhibits 20S proteasome chymotrypsin-like activity.
- The proteinase inhibitor Kaletra, which is a mixture of the HIV-1 proteinase inhibitors lopinavir and ritonavir has been shown to be effective against SARS-CoV and MERS-CoV.
- Shown in a SARS-CoV-2 protease structure model study to potentially bind and inhibit the coronavirus endopeptidase C30 (CEP_C30) of SARS-CoV-2. An initial randomized trial study was not successful.
- ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans: D.J. Kempf, et al.; PNAS 92, 2484 (1995)
- Discovery of ritonavir, a potent inhibitor of HIV protease with high oral bioavailability and clinical efficacy: D.J. Kempf, et al.; J. Med. Chem. 41, 602 (1998)
- How an Inhibitor of the HIV-I Protease Modulates Proteasome Activity: G. Schmidtke, et al.; J. Biol. Chem. 274, 35734 (1999)
- Pharmacological and therapeutic properties of ritonavir-boosted protease inhibitor therapy in HIV-infected patients: R.K. Zeldin, et al.; J. Antimicrob. Chemother. 53, 4 (2004)
- Molecular dynamic simulations analysis of ritonavir and lopinavir as SARS-CoV 3CL(pro) inhibitors: V. Nukoolkarn, et al.; J. Theor. Biol. 254, 861 (2008)
- HIV protease inhibitors act as competitive inhibitors of the cytoplasmic glucose binding site of GLUTs with differing affinities for GLUT1 and GLUT4: R.C. Hresko & P.W. Hruz; PLoS One 6, e25237 (2011)
- Targeting Glycolysis and Compensatory Mitochondrial Metabolism In An In Vivo Xenograft Model Of Multiple Myeloma With FDA Approved Ritonavir and Metformin: S. Dalva-Aydemir, et al.; Blood 122, 1922 (2013)
- Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis: T. Liu, et al.; Cell Death Dis. 5, e1470 (2014)
- In Silico Modeling-based Identification of Glucose Transporter 4 (GLUT4)-selective Inhibitors for Cancer Therapy: R.K. Mishra, et al.; J. Biol. Chem. 290, 14441 (2015)
- A guide to immunometabolism for immunologists: L.A. O'Neill, et al.; Nat. Rev. Immunol. 16, 553 (2016)
- Development of GLUT4-selective antagonists for multiple myeloma therapy: C. Wei, et al.; Eur. J. Med. Chem. 139, 573 (2017)
- Molecular Modeling Evaluation of the Binding Effect of Ritonavir, Lopinavir and Darunavir to Severe Acute Respiratory Syndrome Coronavirus 2 Proteases: S. Lin, et al.; (Epub ahead of print) (2020)
- A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19: B. Cao, et al.; N. Engl. J. Med. (Epub ahead of print) (2020)